Michael B. Atkins
Georgetown University · 1,130 works · 100,029 citations · h-index 125
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Comprehensive molecular characterization of clear cell renal cell carcinoma
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Management of Cutaneous Melanoma
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
- High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
- Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain